March 2018 Awareness Night How clinical trials have changed prostate cancer care Dr. Andrew Loblaw BSc MD MSc FRCPC CIP Clinician Scientist , Ontario Association of Radiation OncologyStaff Radiation Oncologist & Clinician Scientist, Sunnybrook Health Sciences Centre Scientist, Sunnybrook Research Institute Fellow, American Society of Clinical Oncology (ASCO) Co-Chair, GU group for Cancer Care Ontario’s Program in Evidence-Based Care Previous Co-Chair, ASCO’s Genitourinary Advisory Group Professor, Department of Radiation Oncology at University of Toronto Professor,The Institute of Health Policy, Management and Evaluation (IHPME) CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 66:27 minutes
Awareness: The PCCN-Toronto and Side by Side Prostate Cancer Support Groups Newsletter. In this Issue: April Fools page Giampaolo (Paul) Fiaschi – 1933-2018 Ask the Health Care Team (was Ask the Doctor) – Prostate Cancer and Exercise Coming Awareness Night – Carrie Poteck (M.Ed.) – An evening on exercise, diet and well being! June 17th, 2018 is our Father`s Day “Do It For Dads” walk/run at Ashbridges Bay January Janssen Awareness Night: Dr. Stanley Flax & Dr. Adam Tunis – Perineal biopsies and the role of imaging March Awareness Night: Dr. Andrew Loblaw – How clincal trials have changed prostate
A substantial proportion of men with low-risk prostate cancer can safely be followed with a de-intensified active surveillance protocol. Read the article here.
For men with metastatic prostate cancer there is no survival advantage for aggressive therapy over conservative androgen deprivation therapy only, according to a study. Read the article here.
A greater than 90-day delay from prostate biopsy to radical prostatectomy for localized prostate cancer may increase the risk of biochemical recurrence of disease, according to study findings. Read the article here.
Gay men with prostate cancer have unmet information and supportive care needs throughout their prostate cancer journey. Read the article here.
A new study shows that a mix of different treatments, or a “multimodal” approach to prostate cancer therapy, lengthens survival in men who have this diagnosis. Read the article here.
A drug used to treat enlarged prostate or hair loss in men has been shown to have a long-term protective effect against prostate cancer. Read the article here.
Repeat prostate biopsies prior to radical prostatectomy do not impact erectile function recovery and mid‐ to long‐term continence
Repeat biopsy before radical prostatectomy impairs early continence after surgery. However, erectile function recovery and mid‐term to long‐term continence are not affected. These data support the current trend towards active surveillance and delayed local treatment in patients with low‐ to intermediate‐risk prostate cancer. Read the article here.
A new study shows that higher doses of radiation do not improve survival for many patients with prostate cancer, compared with the standard radiation treatment. Read the article here.